TMEM87B

Across TCGA pan-cancer cohorts, TMEM87B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM87B data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM87B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM87B expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

CCRCC, HNSC, and COAD are the cancer types where TMEM87B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.737	0.942	<.001	105	view →
HNSC	DFS	Tertile	II,III,IV	0.871	0.664	.003	47	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.796	.031	36	view →
LUAD	DFS	Tertile	All	0.484	0.895	<.001	20	view →
GBM	DFS	Quartile	All	0.226	0.470	.008	9	view →
PDAC	OS	Median	IV	0.381	0.951	.006	6	view →
LSCC	DFS	Median	All	0.902	0.979	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM87B–CCRCC (OS)

Open the CCRCC breakdown →